136 related articles for article (PubMed ID: 9704868)
21. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
Zohar J; Insel TR
Biol Psychiatry; 1987 Jun; 22(6):667-87. PubMed ID: 3036259
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.
Mueller EA; Murphy DL; Sunderland T
J Clin Endocrinol Metab; 1985 Dec; 61(6):1179-84. PubMed ID: 4055985
[TBL] [Abstract][Full Text] [Related]
23. Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa.
Hadigan CM; Walsh BT; Buttinger C; Hollander E
Biol Psychiatry; 1995 Apr; 37(8):504-11. PubMed ID: 7619973
[TBL] [Abstract][Full Text] [Related]
24. The serotonin hypothesis of obsessive compulsive disorder.
Barr LC; Goodman WK; Price LH
Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():79-82. PubMed ID: 8201248
[TBL] [Abstract][Full Text] [Related]
25. Increased cerebral blood flow during m-CPP exacerbation of obsessive-compulsive disorder.
Hollander E; Prohovnik I; Stein DJ
J Neuropsychiatry Clin Neurosci; 1995; 7(4):485-90. PubMed ID: 8555752
[TBL] [Abstract][Full Text] [Related]
26. A preliminary study of buspirone stimulated prolactin release in generalised social phobia: evidence for enhanced serotonergic responsivity?
Condren RM; Dinan TG; Thakore JH
Eur Neuropsychopharmacol; 2002 Aug; 12(4):349-54. PubMed ID: 12126875
[TBL] [Abstract][Full Text] [Related]
27. Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics.
Buydens-Branchey L; Branchey M; Fergeson P; Hudson J; McKernin C
Alcohol Clin Exp Res; 1997 Apr; 21(2):220-6. PubMed ID: 9113256
[TBL] [Abstract][Full Text] [Related]
28. Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT(1A) receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects.
Schwartz PJ; Turner EH; Garcia-Borreguero D; Sedway J; Vetticad RG; Wehr TA; Murphy DL; Rosenthal NE
Psychiatry Res; 1999 Apr; 86(1):9-28. PubMed ID: 10359479
[TBL] [Abstract][Full Text] [Related]
29. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW
Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202
[TBL] [Abstract][Full Text] [Related]
30. The anterior pituitary responds normally to protirelin in obsessive-compulsive disorder: evidence to support a neuroendocrine serotonergic deficit.
Lucey JV; Butcher G; Clare AW; Dinan TG
Acta Psychiatr Scand; 1993 Jun; 87(6):384-8. PubMed ID: 8356888
[TBL] [Abstract][Full Text] [Related]
31. Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy controls.
Hollander E; DeCaria C; Nitescu A; Cooper T; Stover B; Gully R; Klein DF; Liebowitz MR
Psychiatry Res; 1991 May; 37(2):161-77. PubMed ID: 1876628
[TBL] [Abstract][Full Text] [Related]
32. Headache and cortisol responses to m-chlorophenylpiperazine are highly correlated.
Gordon ML; Lipton RB; Brown SL; Nakraseive C; Russell M; Pollack SZ; Korn ML; Merriam A; Solomon S; van Praag HM
Cephalalgia; 1993 Dec; 13(6):400-5. PubMed ID: 8313453
[TBL] [Abstract][Full Text] [Related]
33. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood.
Riedel WJ; Klaassen T; Griez E; Honig A; Menheere PP; van Praag HM
Neuropsychopharmacology; 2002 Mar; 26(3):358-67. PubMed ID: 11850150
[TBL] [Abstract][Full Text] [Related]
34. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.
Katzman MA; Koszycki D; Bradwejn J
Depress Anxiety; 2004; 20(2):51-8. PubMed ID: 15390214
[TBL] [Abstract][Full Text] [Related]
35. The effect of m-CPP on tics and obsessive-compulsive phenomena in Gilles de la Tourette syndrome.
Cath DC; Gijsman HJ; Schoemaker RC; van Griensven JM; Troost N; van Kempen GM; Cohen AF
Psychopharmacology (Berl); 1999 May; 144(2):137-43. PubMed ID: 10394994
[TBL] [Abstract][Full Text] [Related]
36. Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects. Diurnal responses and nocturnal regulatory mechanisms.
Schwartz PJ; Murphy DL; Wehr TA; Garcia-Borreguero D; Oren DA; Moul DE; Ozaki N; Snelbaker AJ; Rosenthal NE
Arch Gen Psychiatry; 1997 Apr; 54(4):375-85. PubMed ID: 9107154
[TBL] [Abstract][Full Text] [Related]
37. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment.
Broocks A; Briggs NC; Pigott TA; Hill JL; Canter SK; Tolliver TJ; Baldemore D; Murphy DL
Psychopharmacology (Berl); 1997 Mar; 130(2):91-103. PubMed ID: 9106905
[TBL] [Abstract][Full Text] [Related]
38. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL
Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283
[TBL] [Abstract][Full Text] [Related]
39. Buspirone induced prolactin responses in obsessive-compulsive disorder (OCD): is OCD a 5-HT2 receptor disorder?
Lucey JV; Butcher G; Clare AW; Dinan TG
Int Clin Psychopharmacol; 1992; 7(1):45-9. PubMed ID: 1624756
[TBL] [Abstract][Full Text] [Related]
40. Cortisol response to d-fenfluramine in patients with obsessive-compulsive disorder and in healthy subjects: evidence for a gender-related effect.
Monteleone P; Catapano F; Tortorella A; Maj M
Neuropsychobiology; 1997; 36(1):8-12. PubMed ID: 9211437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
